Skip to main content

Table 2 Univariate analysis of predictive variables for DFS and OS

From: Which factors predict tumor recurrence and survival after curative hepatectomy in hepatocellular carcinoma? Results from a European institution

Variables

Number (n;%)

DFS HR (95% CI)

P-value

OS HR (95% CI)

P-value

Age

 

1.018 (0.646–1.603)

0.939

1.522 (1.040–2.227)

0.027

 ≥ 70 years

89 (47.34)

    

 < 70 years

99 (52.66)

    

Sex

 

0.831 (0.503–1.373)

0.464

1.031 (0.654–1.627)

0.894

Male

142(75.53)

    

Female

46 (24.47)

    

BMI

 

0.744 (0.475–1.165)

0.190

0.693 (0.473–1.013)

0.054

 ≥ 25.97 kg/m2

92 (48.93)

    

 < 25.97 kg/m2

96 (51.07)

    

ASA Score

 

0.755 (0.480–1.187)

0.217

1.271 (0.846–1.909)

0.242

I/II

64 (34.04)

    

III/IV

124(65.96)

    

Hepatitis A

 

0.401 (0.146–1.100)

0.064

0.965 (0.517–1.801)

0.909

Yes

20 (10.64)

    

No

168 (89.36)

    

Hepatitis B

 

1.101 (0.661–1.833)

0.709

0.720 (0.442–1.170)

0.178

Yes

42 (22.34)

    

No

146 (77.66)

    

Hepatitis C

 

0.723 (0.426–1.226)

0.222

0.829 (0.536–1.281)

0.392

Yes

56 (29.79)

    

No

132 (70.21)

    

Child–Pugh Score

 

0.991 (0.628–1.563)

0.964

1.419 (0.966–2.084)

0.018

No cirrhosis

22 (11.70)

    

A

143 (76.06)

    

B

22 (11.70)

    

C

1 (0.53)

    

Co-morbidity

 Cardiac

 

0.666 (0.392–1.130)

0.126

1.310 (0.885–1.939)

0.170

 Yes

65 (34.57)

    

 No

123 (65.43)

    

 Pulmonary

 

1.039 (0.612–1.763)

0.888

1.301 (0.853–1.984)

0.214

 Yes

43 (22.87)

    

 No

145 (77.13)

    

 Renal insufficiency

 

0.740 (0.356–1.541)

0.415

1.159 (0.681–1.973)

0.580

 Yes

27 (14.36)

    

 No

161 (85.64)

    

 Diabetes mellitus

 

1.402 (0.887–2.215)

0.142

1.491 (1.010–2.200)

0.040

 Yes

64 (34.04)

    

 No

124 (65.6)

    

 Chronic alcohol abuse

 

1.736 (1.052–2.866)

0.027

1.121 (0.716–1.754)

0.614

 Yes

37 (19.68)

    

 No

151 (80.32)

    

 MELD Score

 

1.323 (0.842–2.078)

0.218

1.360 (0.926–1.999)

0.111

  ≥ 8

107 (56.91)

    

  < 8

81 (43.09)

    

 Tumor Diameter

 

1.697 (1.081–2.666)

0.019

1.715 (1.164–2.526)

0.005

  ≥ 45 mm

97 (51.59)

    

  < 45 mm

91 (48.41)

    

 Single lesion

111 (59.04)

1.259 (0.806–1.968)

0.306

1.284 (0.880–1.873)

0.188

 Multiple lesions

77 (40.96

    

 Unilobular lesion(s)

134 (71.28)

1.455 (0.898–2.355)

0.121

1.292 (0.863–1.935)

0.206

 Bilobular lesions

54 (28.72)

    

 T-Stage

 

1.129 (0.642–1.985)

0.669

1.583 (1.029–2.436)

0.033

 I/II

149 (79.26)

    

 III/IV

39 (20.74)

    

 M-Stage

 

6.672(1.554–28.642)

0.003

5.106 (2.043–12.760)

 < 0.0001

 M0

183 (97.34)

    

 M1

5 (2.66)

    

 Grade

 

1.284 (0.677–2.438)

0.438

1.773 (1.085–2.896)

0.019

 I/II

157 (83.51)

    

 III/IV

31 (16.49)

    

Resection margin

 R < 0.1 cm

33 (17.55)

1.216 (0.701–2.107)

0.482

1.174 (0.729–1.892)

0.504

 R > 0.1 cm

155 (82.45)

    

 R < 0.5 cm

72 (38.30)

1.105 (0.698–1.751)

0.667

0.906 (0.617–1.330)

0.610

 R > 0.5 cm

116 (61.70)

    

 L-Stage

 

1.708 (0.623–4.683)

0.288

2.833 (1.370–5.859)

0.003

 L0

178 (94.68)

    

 L1

10 (5.32)

    

 V-Stage

 

0.811 (0.406–1.622)

0.594

2.249 (1.539–3.287)

 < 0.0001

 V0

156 (82.98)

    

 V1 (micro)

29 (15.43)

    

 V2 (macro)

3 (1.60)

    

 UICC-Stage

 

1.267 (0.962–1.669)

0.006

1.512 (1.227–1.863)

 < 0.0001

 I

111 (59.04)

    

 II

43 (22.87)

    

 III

28 (14.89)

    

 IV

6 (3.19)

    

 ISLT/PVE

 

1.393 (0.561–3.454)

0.468

1.839 (0.984–3.434)

0.049

 Yes

15 (7.98)

    

 No

173 (92.02)

    

 Segments ≥ 3

 

1.171 (0.745–1.842)

0.489

1.783 (1.221–2.606)

0.002

 Yes

83 (44.15)

    

 No

105 (55.85)

    

 Biliary reconstruction

 

1.162 (0.364–3.707)

0.797

2.417 (1.323–4.416)

0.003

 Yes

14 (7.45)

    

 No

174 (92.55)

    

 T-Drainage

 

1.456 (0.874–2.425)

0.143

0.902 (0.560–1.453)

0.667

 Yes

38 (20.21)

    

 No

150 (79.79)

    

 Operative time

 

0.710 (0.451–1.118)

0.134

1.356 (0.927–1.984)

0.111

  ≥ 307 min

94 (50.00)

    

  < 307 min

94 (50.00)

    

 Intraoperative transfusion

 

0.708 (0.437–1.147)

0.155

1.248 (0.852–1.828)

0.248

 Yes

74 (39.36)

    

 No

114 (60.64)

    

 CD ≥ 3a

 

1.351 (0.845–2.160)

0.202

2.272 (1.555–3.319)

 < 0.0001

 Yes

73 (38.83)

    

 No

115 (61.17)

    

 Bile leak

 

1.168 (0.600–2.276)

0.644

0.966 (0.529–1.761)

0.908

 Yes

20 (10.64)

    

 No

168 (89.36)

    

 Intra-abdominal abscess

 

4.152 (2.036–8.467)

 < 0.0001

1.755 (0.982–3.137)

0.051

 Yes

14 (7.45)

    

 No

174 (92.55)

    

 Cholangitis

 

0.829 (0.203–3.386)

0.792

2.885 (1.541–5.402)

 < 0.0001

 Yes

13 (6.91)

    

 No

175 (93.09)

    

 Sepsis

 

1.218 (0.161–9.221)

0.847

19.225 (9.947–37.159)

 < 0.0001

 Yes

19 (10.11)

    

 No

169 (89.89)

    

 Wound infection

 

0.948 (0.486–1.846)

0.873

1.332 (0.802–2.210)

0.260

 Yes

24 (12.77)

    

 No

164 (87.23)

    

 ISGLS B/C

 

1.287 (0.755–2.193)

0.347

2.992 (2.026–4.420)

 < 0.0001

 Yes

58 (30.85)

    

 No

130 (69.15)

    
  1. ASA American Society of Anesthesiologists, BMI body mass index, CD Clavien-Dindo, HR hazard ratios, ISGLS International Study Group of Liver Surgery, ISLT/PVE in situ split plus portal vein ligation/portal venous embolization, MELD Model of End Stage Liver Disease, UICC Union internationale contre le cancer